Last reviewed · How we verify
Placebo to rizatriptan tablets
Placebo to rizatriptan tablets is a Triptan (5-HT1B/1D receptor agonist) Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Acute treatment of migraine with or without aura in adults.
Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist that constricts cranial blood vessels and inhibits neuropeptide release to relieve migraine headaches.
Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist that constricts cranial blood vessels and inhibits neuropeptide release to relieve migraine headaches. Used for Acute treatment of migraine with or without aura in adults.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression). -
Big-pharma sponsor
+3.0pp
Merck Sharp & Dohme LLC is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Placebo to rizatriptan tablets |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Triptan (5-HT1B/1D receptor agonist) |
| Target | 5-HT1B receptor, 5-HT1D receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Rizatriptan binds to 5-HT1B and 5-HT1D receptors on intracranial blood vessels and trigeminal nerve terminals. This causes vasoconstriction of dilated cranial arteries and reduces the release of vasoactive neuropeptides involved in migraine pathophysiology, thereby terminating acute migraine attacks.
Approved indications
- Acute treatment of migraine with or without aura in adults
Common side effects
- Dizziness
- Somnolence
- Asthenia/fatigue
- Chest pain/pressure
- Palpitations
- Nausea
Key clinical trials
- Initiating Early Control of Migraine Pain and Associated Symptoms (PHASE3)
- Efficacy and Safety of Rizatriptan-Naproxen (10/550 Mg) in the Acute Treatment of Migraine (PHASE3)
- Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072) (PHASE3)
- Study to Test an Approved Product in the Early Treatment of Migraine (0462-066) (PHASE3)
- Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071) (PHASE3)
- Study to Test an Approved Product in the Early Treatment of Migraine (0462-065) (PHASE3)
- A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis (PHASE3)
- A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to rizatriptan tablets CI brief — competitive landscape report
- Placebo to rizatriptan tablets updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Placebo to rizatriptan tablets
What is Placebo to rizatriptan tablets?
How does Placebo to rizatriptan tablets work?
What is Placebo to rizatriptan tablets used for?
Who makes Placebo to rizatriptan tablets?
What drug class is Placebo to rizatriptan tablets in?
What development phase is Placebo to rizatriptan tablets in?
What are the side effects of Placebo to rizatriptan tablets?
What does Placebo to rizatriptan tablets target?
Related
- Drug class: All Triptan (5-HT1B/1D receptor agonist) drugs
- Target: All drugs targeting 5-HT1B receptor, 5-HT1D receptor
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Acute treatment of migraine with or without aura in adults
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing